nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA1—renal system—muscle cancer	0.0193	0.0659	CbGeAlD
Lithium—GSK3B—embryo—muscle cancer	0.0188	0.0641	CbGeAlD
Lithium—IMPA2—Teniposide—Etoposide—muscle cancer	0.0173	1	CbGdCrCtD
Lithium—GSK3B—smooth muscle tissue—muscle cancer	0.0148	0.0504	CbGeAlD
Lithium—IMPA2—renal system—muscle cancer	0.0145	0.0494	CbGeAlD
Lithium—GSK3B—renal system—muscle cancer	0.0142	0.0485	CbGeAlD
Lithium—IMPA2—cardiac atrium—muscle cancer	0.013	0.0443	CbGeAlD
Lithium—IMPA1—head—muscle cancer	0.0129	0.0441	CbGeAlD
Lithium—GSK3A—smooth muscle tissue—muscle cancer	0.0129	0.0438	CbGeAlD
Lithium—IMPA1—testis—muscle cancer	0.0125	0.0426	CbGeAlD
Lithium—GSK3A—renal system—muscle cancer	0.0124	0.0422	CbGeAlD
Lithium—IMPA2—tendon—muscle cancer	0.0113	0.0386	CbGeAlD
Lithium—GSK3A—cardiac atrium—muscle cancer	0.0111	0.0378	CbGeAlD
Lithium—GRIA3—head—muscle cancer	0.011	0.0375	CbGeAlD
Lithium—IMPA2—bone marrow—muscle cancer	0.011	0.0374	CbGeAlD
Lithium—GRIA3—testis—muscle cancer	0.0106	0.0362	CbGeAlD
Lithium—IMPA2—vagina—muscle cancer	0.0105	0.0358	CbGeAlD
Lithium—GSK3B—vagina—muscle cancer	0.0103	0.0351	CbGeAlD
Lithium—Optic atrophy—Vincristine—muscle cancer	0.0101	0.0778	CcSEcCtD
Lithium—GSK3A—tendon—muscle cancer	0.00967	0.0329	CbGeAlD
Lithium—GSK3B—head—muscle cancer	0.00953	0.0324	CbGeAlD
Lithium—IMPA2—testis—muscle cancer	0.00938	0.0319	CbGeAlD
Lithium—GSK3A—bone marrow—muscle cancer	0.00937	0.0319	CbGeAlD
Lithium—GSK3B—testis—muscle cancer	0.00921	0.0313	CbGeAlD
Lithium—GSK3A—vagina—muscle cancer	0.00897	0.0305	CbGeAlD
Lithium—GSK3A—head—muscle cancer	0.00829	0.0282	CbGeAlD
Lithium—GSK3A—testis—muscle cancer	0.00801	0.0273	CbGeAlD
Lithium—Blindness—Vincristine—muscle cancer	0.00348	0.0269	CcSEcCtD
Lithium—Folliculitis—Dactinomycin—muscle cancer	0.00343	0.0266	CcSEcCtD
Lithium—Taste metallic—Methotrexate—muscle cancer	0.00294	0.0228	CcSEcCtD
Lithium—Nystagmus—Vincristine—muscle cancer	0.0027	0.0209	CcSEcCtD
Lithium—Optic neuritis—Etoposide—muscle cancer	0.00254	0.0196	CcSEcCtD
Lithium—GSK3B—ErbB Signaling Pathway—MDM2—muscle cancer	0.00184	0.00328	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.00182	0.00325	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—FOXO4—muscle cancer	0.00181	0.00324	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—FOXO1—muscle cancer	0.00181	0.00323	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO1—muscle cancer	0.0018	0.00321	CbGpPWpGaD
Lithium—Chest discomfort—Etoposide—muscle cancer	0.00177	0.0137	CcSEcCtD
Lithium—GSK3B—p53 pathway—CDKN2A—muscle cancer	0.00176	0.00315	CbGpPWpGaD
Lithium—Coma—Vincristine—muscle cancer	0.00176	0.0136	CcSEcCtD
Lithium—Urine output increased—Vincristine—muscle cancer	0.00174	0.0135	CcSEcCtD
Lithium—GSK3A—Insulin Signaling—FOXO1—muscle cancer	0.00174	0.0031	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—FOXO4—muscle cancer	0.00173	0.00309	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—FOXO1—muscle cancer	0.00173	0.00309	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—FOXO4—muscle cancer	0.00172	0.00308	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—FOXO1—muscle cancer	0.00172	0.00307	CbGpPWpGaD
Lithium—GSK3A—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	0.00171	0.00306	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—FOXO4—muscle cancer	0.00171	0.00306	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—FOXO1—muscle cancer	0.00171	0.00306	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—MDM2—muscle cancer	0.00171	0.00306	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—FOXO4—muscle cancer	0.0017	0.00305	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—FOXO1—muscle cancer	0.0017	0.00304	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—muscle cancer	0.00168	0.003	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MYOG—muscle cancer	0.00168	0.003	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.00168	0.003	CbGpPWpGaD
Lithium—IMPA1—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.00166	0.00297	CbGpPWpGaD
Lithium—GSK3B—Aurora A signaling—TP53—muscle cancer	0.00164	0.00294	CbGpPWpGaD
Lithium—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—muscle cancer	0.00162	0.00289	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—KIT—muscle cancer	0.00161	0.00287	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—FOXO4—muscle cancer	0.0016	0.00287	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—FOXO4—muscle cancer	0.0016	0.00287	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.0016	0.00287	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—FOXO1—muscle cancer	0.0016	0.00286	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—FOXO1—muscle cancer	0.0016	0.00286	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.0016	0.00286	CbGpPWpGaD
Lithium—Lethargy—Dactinomycin—muscle cancer	0.0016	0.0124	CcSEcCtD
Lithium—Polyuria—Vincristine—muscle cancer	0.00159	0.0123	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR—FOXO4—muscle cancer	0.00159	0.00284	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—FOXO1—muscle cancer	0.00159	0.00284	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.00158	0.00281	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.00157	0.00281	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—FOXO4—muscle cancer	0.00157	0.0028	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—FOXO1—muscle cancer	0.00157	0.0028	CbGpPWpGaD
Lithium—GSK3A—PI-3K cascade—MDM2—muscle cancer	0.00154	0.00276	CbGpPWpGaD
Lithium—IMPA2—Metabolism—MED12—muscle cancer	0.00152	0.00272	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—MDM2—muscle cancer	0.00151	0.00269	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—MDM2—muscle cancer	0.00149	0.00267	CbGpPWpGaD
Lithium—Folliculitis—Methotrexate—muscle cancer	0.00149	0.0115	CcSEcCtD
Lithium—Psoriasis—Methotrexate—muscle cancer	0.00149	0.0115	CcSEcCtD
Lithium—GSK3B—B Cell Activation—FOXO4—muscle cancer	0.00148	0.00265	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—FOXO1—muscle cancer	0.00148	0.00265	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—FOXO4—muscle cancer	0.00148	0.00264	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—KIT—muscle cancer	0.00147	0.00262	CbGpPWpGaD
Lithium—Blindness—Doxorubicin—muscle cancer	0.00146	0.0113	CcSEcCtD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	0.00146	0.00261	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—KIT—muscle cancer	0.00145	0.00259	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—FOXO1—muscle cancer	0.00142	0.00254	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.00142	0.00254	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.00142	0.00254	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—KIT—muscle cancer	0.00141	0.00253	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—KIT—muscle cancer	0.0014	0.00251	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—KIT—muscle cancer	0.0014	0.0025	CbGpPWpGaD
Lithium—IMPA2—Metabolism—ENO2—muscle cancer	0.00139	0.00248	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—KIT—muscle cancer	0.00138	0.00246	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	0.00137	0.00245	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.00136	0.00243	CbGpPWpGaD
Lithium—IMPA1—Metabolism—MED12—muscle cancer	0.00136	0.00243	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—FOXO1—muscle cancer	0.00134	0.00239	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—KIT—muscle cancer	0.00132	0.00235	CbGpPWpGaD
Lithium—Optic neuritis—Doxorubicin—muscle cancer	0.00132	0.0102	CcSEcCtD
Lithium—Ataxia—Vincristine—muscle cancer	0.00132	0.0102	CcSEcCtD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	0.00132	0.00235	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—KIT—muscle cancer	0.00131	0.00234	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—KIT—muscle cancer	0.0013	0.00233	CbGpPWpGaD
Lithium—Dehydration—Vincristine—muscle cancer	0.0013	0.0101	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—HMGA1—muscle cancer	0.0013	0.00232	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—KIT—muscle cancer	0.0013	0.00232	CbGpPWpGaD
Lithium—Folliculitis—Doxorubicin—muscle cancer	0.00129	0.00997	CcSEcCtD
Lithium—Psoriasis—Doxorubicin—muscle cancer	0.00129	0.00997	CcSEcCtD
Lithium—Swelling—Etoposide—muscle cancer	0.00129	0.00994	CcSEcCtD
Lithium—GSK3B—Insulin Signaling—FOXO1—muscle cancer	0.00128	0.00229	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.00128	0.00229	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—FOXO1—muscle cancer	0.00128	0.00228	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—FOXO1—muscle cancer	0.00127	0.00227	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	0.00127	0.00226	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—FOXO1—muscle cancer	0.00127	0.00226	CbGpPWpGaD
Lithium—GSK3B—LKB1 signaling events—TP53—muscle cancer	0.00126	0.00226	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—FOXO1—muscle cancer	0.00126	0.00225	CbGpPWpGaD
Lithium—Stupor—Methotrexate—muscle cancer	0.00125	0.0097	CcSEcCtD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.00124	0.00222	CbGpPWpGaD
Lithium—IMPA1—Metabolism—ENO2—muscle cancer	0.00124	0.00221	CbGpPWpGaD
Lithium—Muscular weakness—Vincristine—muscle cancer	0.00123	0.00955	CcSEcCtD
Lithium—GSK3B—Androgen receptor signaling pathway—MDM2—muscle cancer	0.00123	0.0022	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—KIT—muscle cancer	0.00122	0.00218	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—KIT—muscle cancer	0.00122	0.00218	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.00122	0.00218	CbGpPWpGaD
Lithium—GRIA3—Transmission across Chemical Synapses—MDM2—muscle cancer	0.00122	0.00217	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—KIT—muscle cancer	0.00121	0.00216	CbGpPWpGaD
Lithium—Skin ulcer—Methotrexate—muscle cancer	0.0012	0.0093	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR in Cancer—KIT—muscle cancer	0.0012	0.00214	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—KIT—muscle cancer	0.00119	0.00213	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD34—muscle cancer	0.00119	0.00213	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—FOXO1—muscle cancer	0.00118	0.00212	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.00118	0.00212	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—FOXO1—muscle cancer	0.00118	0.00212	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—FOXO1—muscle cancer	0.00117	0.0021	CbGpPWpGaD
Lithium—Hypercalcaemia—Doxorubicin—muscle cancer	0.00117	0.00902	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.00116	0.00208	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—FOXO1—muscle cancer	0.00116	0.00207	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—MDM2—muscle cancer	0.00115	0.00206	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—MDM2—muscle cancer	0.00114	0.00204	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—CDKN2A—muscle cancer	0.00114	0.00203	CbGpPWpGaD
Lithium—Nystagmus—Doxorubicin—muscle cancer	0.00113	0.00877	CcSEcCtD
Lithium—GSK3A—B Cell Activation—KIT—muscle cancer	0.00113	0.00202	CbGpPWpGaD
Lithium—Erectile dysfunction—Vincristine—muscle cancer	0.00111	0.00862	CcSEcCtD
Lithium—GSK3B—PI3K/AKT activation—MDM2—muscle cancer	0.00111	0.00199	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.00111	0.00199	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—MDM2—muscle cancer	0.0011	0.00197	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—MDM2—muscle cancer	0.0011	0.00197	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.0011	0.00197	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—FOXO1—muscle cancer	0.0011	0.00196	CbGpPWpGaD
Lithium—Weight decreased—Vincristine—muscle cancer	0.00109	0.00847	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—FOXO4—muscle cancer	0.00109	0.00195	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.00109	0.00195	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—FOXO1—muscle cancer	0.00109	0.00195	CbGpPWpGaD
Lithium—GSK3B—Copper homeostasis—TP53—muscle cancer	0.00109	0.00194	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—MDM2—muscle cancer	0.00109	0.00194	CbGpPWpGaD
Lithium—Albuminuria—Doxorubicin—muscle cancer	0.00109	0.0084	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—KIT—muscle cancer	0.00108	0.00193	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.00108	0.00193	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—CDKN2A—muscle cancer	0.00108	0.00193	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.00108	0.00193	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	0.00108	0.00193	CbGpPWpGaD
Lithium—Scotoma—Doxorubicin—muscle cancer	0.00107	0.00825	CcSEcCtD
Lithium—GSK3B—ErbB Signaling Pathway—TP53—muscle cancer	0.00105	0.00188	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.00105	0.00187	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—MDM2—muscle cancer	0.00105	0.00187	CbGpPWpGaD
Lithium—Skin ulcer—Doxorubicin—muscle cancer	0.00104	0.00805	CcSEcCtD
Lithium—GSK3B—Developmental Biology—MYOD1—muscle cancer	0.00104	0.00185	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—MDM2—muscle cancer	0.00104	0.00185	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—KIT—muscle cancer	0.00104	0.00185	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—MDM2—muscle cancer	0.00103	0.00184	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—MDM2—muscle cancer	0.00103	0.00184	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—MDM2—muscle cancer	0.00102	0.00183	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—KIT—muscle cancer	0.00102	0.00182	CbGpPWpGaD
Lithium—Oliguria—Methotrexate—muscle cancer	0.00102	0.00785	CcSEcCtD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.00101	0.0018	CbGpPWpGaD
Lithium—Glycosuria—Doxorubicin—muscle cancer	0.001	0.00774	CcSEcCtD
Lithium—Dysarthria—Methotrexate—muscle cancer	0.000989	0.00765	CcSEcCtD
Lithium—GSK3B—p53 pathway—TP53—muscle cancer	0.000982	0.00175	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—KIT—muscle cancer	0.000974	0.00174	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—KIT—muscle cancer	0.000969	0.00173	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—KIT—muscle cancer	0.000964	0.00172	CbGpPWpGaD
Lithium—Hallucination—Vincristine—muscle cancer	0.000964	0.00745	CcSEcCtD
Lithium—GSK3A—Signaling by FGFR in disease—MDM2—muscle cancer	0.000962	0.00172	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—MDM2—muscle cancer	0.000962	0.00172	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000962	0.00172	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—KIT—muscle cancer	0.000959	0.00171	CbGpPWpGaD
Lithium—Alopecia—Dactinomycin—muscle cancer	0.000958	0.00741	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR—MDM2—muscle cancer	0.000953	0.0017	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MED12—muscle cancer	0.000949	0.0017	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.000945	0.00169	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000945	0.00169	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—MDM2—muscle cancer	0.000941	0.00168	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KIDINS220—muscle cancer	0.000938	0.00168	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—MDM2—muscle cancer	0.000933	0.00167	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000905	0.00162	CbGpPWpGaD
Lithium—Depressed level of consciousness—Methotrexate—muscle cancer	0.000903	0.00699	CcSEcCtD
Lithium—GSK3B—DAP12 interactions—KIT—muscle cancer	0.000903	0.00161	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000903	0.00161	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KIT—muscle cancer	0.000903	0.00161	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—KIT—muscle cancer	0.000894	0.0016	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—MDM2—muscle cancer	0.00089	0.00159	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000887	0.00158	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—KIT—muscle cancer	0.000883	0.00158	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD34—muscle cancer	0.00088	0.00157	CbGpPWpGaD
Lithium—Oliguria—Doxorubicin—muscle cancer	0.000879	0.0068	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000872	0.00156	CbGpPWpGaD
Lithium—Dysarthria—Doxorubicin—muscle cancer	0.000857	0.00663	CcSEcCtD
Lithium—Alopecia—Vincristine—muscle cancer	0.000856	0.00662	CcSEcCtD
Lithium—Coma—Methotrexate—muscle cancer	0.000855	0.00661	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—MDM2—muscle cancer	0.000853	0.00152	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000852	0.00152	CbGpPWpGaD
Lithium—Urine output increased—Methotrexate—muscle cancer	0.000846	0.00654	CcSEcCtD
Lithium—GSK3A—Innate Immune System—FOXO4—muscle cancer	0.000843	0.00151	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—KIT—muscle cancer	0.000835	0.00149	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KIT—muscle cancer	0.000832	0.00149	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000829	0.00148	CbGpPWpGaD
Lithium—Coordination abnormal—Doxorubicin—muscle cancer	0.000825	0.00638	CcSEcCtD
Lithium—GSK3B—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000816	0.00146	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—FOXO4—muscle cancer	0.00081	0.00145	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—FOXO1—muscle cancer	0.000807	0.00144	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—MDM2—muscle cancer	0.000803	0.00143	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000799	0.00143	CbGpPWpGaD
Lithium—Discomfort—Dactinomycin—muscle cancer	0.000794	0.00614	CcSEcCtD
Lithium—Salivary hypersecretion—Doxorubicin—muscle cancer	0.000787	0.00609	CcSEcCtD
Lithium—GSK3B—Alzheimers Disease—TP53—muscle cancer	0.000778	0.00139	CbGpPWpGaD
Lithium—Agitation—Vincristine—muscle cancer	0.000775	0.00599	CcSEcCtD
Lithium—Polyuria—Methotrexate—muscle cancer	0.000774	0.00598	CcSEcCtD
Lithium—Oedema—Dactinomycin—muscle cancer	0.00077	0.00596	CcSEcCtD
Lithium—GSK3B—Downstream signal transduction—MDM2—muscle cancer	0.000767	0.00137	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—MDM2—muscle cancer	0.000763	0.00136	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—MDM2—muscle cancer	0.000759	0.00136	CbGpPWpGaD
Lithium—Vertigo—Vincristine—muscle cancer	0.000757	0.00586	CcSEcCtD
Lithium—GSK3B—DAP12 signaling—MDM2—muscle cancer	0.000756	0.00135	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—muscle cancer	0.000755	0.00135	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000745	0.00133	CbGpPWpGaD
Lithium—Coma—Doxorubicin—muscle cancer	0.00074	0.00573	CcSEcCtD
Lithium—Anorexia—Dactinomycin—muscle cancer	0.000734	0.00568	CcSEcCtD
Lithium—Convulsion—Vincristine—muscle cancer	0.00073	0.00565	CcSEcCtD
Lithium—GSK3A—Immune System—CD34—muscle cancer	0.000723	0.00129	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—MDM2—muscle cancer	0.000711	0.00127	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000711	0.00127	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—MDM2—muscle cancer	0.000711	0.00127	CbGpPWpGaD
Lithium—Hypertonia—Doxorubicin—muscle cancer	0.00071	0.00549	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR—MDM2—muscle cancer	0.000704	0.00126	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000702	0.00543	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000698	0.00125	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—MDM2—muscle cancer	0.000695	0.00124	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KIDINS220—muscle cancer	0.000693	0.00124	CbGpPWpGaD
Lithium—Alopecia—Etoposide—muscle cancer	0.000693	0.00536	CcSEcCtD
Lithium—Lethargy—Methotrexate—muscle cancer	0.000693	0.00536	CcSEcCtD
Lithium—Oedema—Vincristine—muscle cancer	0.000688	0.00532	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000687	0.00123	CbGpPWpGaD
Lithium—Decreased appetite—Dactinomycin—muscle cancer	0.000669	0.00518	CcSEcCtD
Lithium—Dysgeusia—Etoposide—muscle cancer	0.000669	0.00517	CcSEcCtD
Lithium—Fatigue—Dactinomycin—muscle cancer	0.000664	0.00514	CcSEcCtD
Lithium—GSK3B—B Cell Activation—MDM2—muscle cancer	0.000658	0.00118	CbGpPWpGaD
Lithium—Anorexia—Vincristine—muscle cancer	0.000656	0.00507	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—MDM2—muscle cancer	0.000655	0.00117	CbGpPWpGaD
Lithium—Hypotension—Vincristine—muscle cancer	0.000643	0.00497	CcSEcCtD
Lithium—Ataxia—Methotrexate—muscle cancer	0.000639	0.00494	CcSEcCtD
Lithium—Feeling abnormal—Dactinomycin—muscle cancer	0.000635	0.00491	CcSEcCtD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—muscle cancer	0.000634	0.00113	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—muscle cancer	0.000634	0.00113	CbGpPWpGaD
Lithium—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00063	0.00487	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.00063	0.00112	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000627	0.00485	CcSEcCtD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.000627	0.00112	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—FOXO4—muscle cancer	0.000623	0.00111	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—FOXO1—muscle cancer	0.000623	0.00111	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000619	0.00111	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KIT—muscle cancer	0.000615	0.0011	CbGpPWpGaD
Lithium—Vertigo—Etoposide—muscle cancer	0.000614	0.00475	CcSEcCtD
Lithium—Body temperature increased—Dactinomycin—muscle cancer	0.000609	0.00471	CcSEcCtD
Lithium—Abdominal pain—Dactinomycin—muscle cancer	0.000609	0.00471	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	0.000601	0.00107	CbGpPWpGaD
Lithium—Loss of consciousness—Etoposide—muscle cancer	0.0006	0.00464	CcSEcCtD
Lithium—Lethargy—Doxorubicin—muscle cancer	0.0006	0.00464	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—FOXO4—muscle cancer	0.000598	0.00107	CbGpPWpGaD
Lithium—Decreased appetite—Vincristine—muscle cancer	0.000598	0.00463	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—FOXO1—muscle cancer	0.000598	0.00107	CbGpPWpGaD
Lithium—Fatigue—Vincristine—muscle cancer	0.000593	0.00459	CcSEcCtD
Lithium—Convulsion—Etoposide—muscle cancer	0.000592	0.00458	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—IGF2—muscle cancer	0.000591	0.00106	CbGpPWpGaD
Lithium—Discomfort—Etoposide—muscle cancer	0.000574	0.00444	CcSEcCtD
Lithium—Gastrointestinal pain—Vincristine—muscle cancer	0.000563	0.00435	CcSEcCtD
Lithium—Confusional state—Etoposide—muscle cancer	0.000562	0.00435	CcSEcCtD
Lithium—GSK3A—Disease—ENO2—muscle cancer	0.000556	0.000994	CbGpPWpGaD
Lithium—Ataxia—Doxorubicin—muscle cancer	0.000553	0.00428	CcSEcCtD
Lithium—Asthenia—Dactinomycin—muscle cancer	0.000552	0.00427	CcSEcCtD
Lithium—Dehydration—Doxorubicin—muscle cancer	0.000547	0.00423	CcSEcCtD
Lithium—Body temperature increased—Vincristine—muscle cancer	0.000544	0.00421	CcSEcCtD
Lithium—Abdominal pain—Vincristine—muscle cancer	0.000544	0.00421	CcSEcCtD
Lithium—Erectile dysfunction—Methotrexate—muscle cancer	0.000541	0.00418	CcSEcCtD
Lithium—Dry skin—Doxorubicin—muscle cancer	0.000539	0.00417	CcSEcCtD
Lithium—GSK3B—Immune System—CD34—muscle cancer	0.000534	0.000954	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDKN2A—muscle cancer	0.000532	0.000951	CbGpPWpGaD
Lithium—Anorexia—Etoposide—muscle cancer	0.000531	0.00411	CcSEcCtD
Lithium—Diarrhoea—Dactinomycin—muscle cancer	0.000527	0.00408	CcSEcCtD
Lithium—Drowsiness—Methotrexate—muscle cancer	0.000523	0.00405	CcSEcCtD
Lithium—GSK3B—Developmental Biology—FOXO1—muscle cancer	0.000521	0.000931	CbGpPWpGaD
Lithium—Hypotension—Etoposide—muscle cancer	0.000521	0.00403	CcSEcCtD
Lithium—Gastritis—Doxorubicin—muscle cancer	0.00052	0.00403	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000519	0.000928	CbGpPWpGaD
Lithium—Muscular weakness—Doxorubicin—muscle cancer	0.000519	0.00401	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—MDM2—muscle cancer	0.000516	0.000922	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—VEGFA—muscle cancer	0.00051	0.000911	CbGpPWpGaD
Lithium—GSK3A—Disease—HMGA1—muscle cancer	0.000506	0.000903	CbGpPWpGaD
Lithium—Somnolence—Etoposide—muscle cancer	0.000495	0.00383	CcSEcCtD
Lithium—Asthenia—Vincristine—muscle cancer	0.000494	0.00382	CcSEcCtD
Lithium—GSK3A—Immune System—FOXO4—muscle cancer	0.000491	0.000878	CbGpPWpGaD
Lithium—Vomiting—Dactinomycin—muscle cancer	0.00049	0.00379	CcSEcCtD
Lithium—Rash—Dactinomycin—muscle cancer	0.000486	0.00376	CcSEcCtD
Lithium—Decreased appetite—Etoposide—muscle cancer	0.000484	0.00375	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—MDM2—muscle cancer	0.000484	0.000865	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PTGS2—muscle cancer	0.000484	0.000864	CbGpPWpGaD
Lithium—Fatigue—Etoposide—muscle cancer	0.00048	0.00372	CcSEcCtD
Lithium—GSK3A—Innate Immune System—KIT—muscle cancer	0.000475	0.000848	CbGpPWpGaD
Lithium—Diarrhoea—Vincristine—muscle cancer	0.000471	0.00364	CcSEcCtD
Lithium—Weight increased—Doxorubicin—muscle cancer	0.000463	0.00358	CcSEcCtD
Lithium—GSK3B—Innate Immune System—FOXO1—muscle cancer	0.00046	0.000822	CbGpPWpGaD
Lithium—Weight decreased—Doxorubicin—muscle cancer	0.00046	0.00356	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—muscle cancer	0.000459	0.00355	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—muscle cancer	0.000459	0.00355	CcSEcCtD
Lithium—Nausea—Dactinomycin—muscle cancer	0.000457	0.00354	CcSEcCtD
Lithium—Gastrointestinal pain—Etoposide—muscle cancer	0.000456	0.00353	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—KIT—muscle cancer	0.000456	0.000814	CbGpPWpGaD
Lithium—Dizziness—Vincristine—muscle cancer	0.000455	0.00352	CcSEcCtD
Lithium—GSK3A—Disease—FOXO4—muscle cancer	0.000453	0.00081	CbGpPWpGaD
Lithium—Drowsiness—Doxorubicin—muscle cancer	0.000453	0.00351	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—FOXO1—muscle cancer	0.000442	0.00079	CbGpPWpGaD
Lithium—Abdominal pain—Etoposide—muscle cancer	0.000441	0.00341	CcSEcCtD
Lithium—Body temperature increased—Etoposide—muscle cancer	0.000441	0.00341	CcSEcCtD
Lithium—Tinnitus—Methotrexate—muscle cancer	0.000438	0.00339	CcSEcCtD
Lithium—Vomiting—Vincristine—muscle cancer	0.000437	0.00338	CcSEcCtD
Lithium—Rash—Vincristine—muscle cancer	0.000434	0.00336	CcSEcCtD
Lithium—Dermatitis—Vincristine—muscle cancer	0.000433	0.00335	CcSEcCtD
Lithium—IMPA1—Metabolism—PTGS2—muscle cancer	0.000431	0.00077	CbGpPWpGaD
Lithium—Headache—Vincristine—muscle cancer	0.000431	0.00333	CcSEcCtD
Lithium—Alopecia—Methotrexate—muscle cancer	0.000415	0.00321	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—muscle cancer	0.000414	0.0032	CcSEcCtD
Lithium—GSK3B—Disease—ENO2—muscle cancer	0.000411	0.000734	CbGpPWpGaD
Lithium—Nausea—Vincristine—muscle cancer	0.000409	0.00316	CcSEcCtD
Lithium—Dysgeusia—Methotrexate—muscle cancer	0.000401	0.0031	CcSEcCtD
Lithium—Asthenia—Etoposide—muscle cancer	0.0004	0.00309	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—VEGFA—muscle cancer	0.000392	0.0007	CbGpPWpGaD
Lithium—Vision blurred—Methotrexate—muscle cancer	0.000385	0.00298	CcSEcCtD
Lithium—Diarrhoea—Etoposide—muscle cancer	0.000381	0.00295	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—muscle cancer	0.000379	0.00293	CcSEcCtD
Lithium—GSK3A—Innate Immune System—MDM2—muscle cancer	0.000374	0.000668	CbGpPWpGaD
Lithium—GSK3B—Disease—HMGA1—muscle cancer	0.000374	0.000667	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTCH1—muscle cancer	0.000369	0.00066	CbGpPWpGaD
Lithium—Dizziness—Etoposide—muscle cancer	0.000369	0.00285	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—TP53—muscle cancer	0.000368	0.000658	CbGpPWpGaD
Lithium—Vertigo—Methotrexate—muscle cancer	0.000367	0.00284	CcSEcCtD
Lithium—Arrhythmia—Doxorubicin—muscle cancer	0.000363	0.00281	CcSEcCtD
Lithium—GSK3B—Immune System—FOXO4—muscle cancer	0.000363	0.000648	CbGpPWpGaD
Lithium—GSK3A—Immune System—FOXO1—muscle cancer	0.000363	0.000648	CbGpPWpGaD
Lithium—Alopecia—Doxorubicin—muscle cancer	0.00036	0.00278	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—MDM2—muscle cancer	0.000359	0.000641	CbGpPWpGaD
Lithium—Convulsion—Methotrexate—muscle cancer	0.000354	0.00274	CcSEcCtD
Lithium—Vomiting—Etoposide—muscle cancer	0.000354	0.00274	CcSEcCtD
Lithium—Rash—Etoposide—muscle cancer	0.000351	0.00272	CcSEcCtD
Lithium—Dermatitis—Etoposide—muscle cancer	0.000351	0.00272	CcSEcCtD
Lithium—GSK3B—Innate Immune System—KIT—muscle cancer	0.000351	0.000627	CbGpPWpGaD
Lithium—Headache—Etoposide—muscle cancer	0.000349	0.0027	CcSEcCtD
Lithium—Flatulence—Doxorubicin—muscle cancer	0.000349	0.0027	CcSEcCtD
Lithium—Arthralgia—Methotrexate—muscle cancer	0.000348	0.00269	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—muscle cancer	0.000347	0.00268	CcSEcCtD
Lithium—Discomfort—Methotrexate—muscle cancer	0.000344	0.00266	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—KIT—muscle cancer	0.000337	0.000602	CbGpPWpGaD
Lithium—Confusional state—Methotrexate—muscle cancer	0.000337	0.0026	CcSEcCtD
Lithium—GSK3B—Disease—FOXO4—muscle cancer	0.000335	0.000599	CbGpPWpGaD
Lithium—GSK3A—Disease—FOXO1—muscle cancer	0.000335	0.000598	CbGpPWpGaD
Lithium—Vision blurred—Doxorubicin—muscle cancer	0.000334	0.00258	CcSEcCtD
Lithium—GSK3B—Axon guidance—VEGFA—muscle cancer	0.000333	0.000595	CbGpPWpGaD
Lithium—Nausea—Etoposide—muscle cancer	0.000331	0.00256	CcSEcCtD
Lithium—Agitation—Doxorubicin—muscle cancer	0.000325	0.00252	CcSEcCtD
Lithium—Vertigo—Doxorubicin—muscle cancer	0.000318	0.00246	CcSEcCtD
Lithium—Anorexia—Methotrexate—muscle cancer	0.000318	0.00246	CcSEcCtD
Lithium—Syncope—Doxorubicin—muscle cancer	0.000318	0.00246	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—FOXO4—muscle cancer	0.000318	0.000567	CbGpPWpGaD
Lithium—Hypotension—Methotrexate—muscle cancer	0.000312	0.00241	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CNR1—muscle cancer	0.000312	0.000557	CbGpPWpGaD
Lithium—Loss of consciousness—Doxorubicin—muscle cancer	0.000311	0.00241	CcSEcCtD
Lithium—Convulsion—Doxorubicin—muscle cancer	0.000307	0.00237	CcSEcCtD
Lithium—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000304	0.00235	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—muscle cancer	0.000302	0.00233	CcSEcCtD
Lithium—Discomfort—Doxorubicin—muscle cancer	0.000298	0.0023	CcSEcCtD
Lithium—Somnolence—Methotrexate—muscle cancer	0.000297	0.0023	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—TP53—muscle cancer	0.000296	0.000529	CbGpPWpGaD
Lithium—Dry mouth—Doxorubicin—muscle cancer	0.000295	0.00228	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—muscle cancer	0.000294	0.00227	CcSEcCtD
Lithium—Confusional state—Doxorubicin—muscle cancer	0.000291	0.00225	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—muscle cancer	0.00029	0.00225	CcSEcCtD
Lithium—Oedema—Doxorubicin—muscle cancer	0.000289	0.00224	CcSEcCtD
Lithium—Fatigue—Methotrexate—muscle cancer	0.000288	0.00223	CcSEcCtD
Lithium—Shock—Doxorubicin—muscle cancer	0.000284	0.0022	CcSEcCtD
Lithium—GSK3A—Immune System—KIT—muscle cancer	0.000276	0.000494	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—MDM2—muscle cancer	0.000276	0.000493	CbGpPWpGaD
Lithium—Anorexia—Doxorubicin—muscle cancer	0.000276	0.00213	CcSEcCtD
Lithium—Feeling abnormal—Methotrexate—muscle cancer	0.000275	0.00213	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—muscle cancer	0.000273	0.00211	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—PTCH1—muscle cancer	0.000273	0.000488	CbGpPWpGaD
Lithium—Hypotension—Doxorubicin—muscle cancer	0.00027	0.00209	CcSEcCtD
Lithium—GSK3B—Immune System—FOXO1—muscle cancer	0.000268	0.000479	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—MDM2—muscle cancer	0.000265	0.000474	CbGpPWpGaD
Lithium—Body temperature increased—Methotrexate—muscle cancer	0.000264	0.00204	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—muscle cancer	0.000264	0.00204	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000263	0.00204	CcSEcCtD
Lithium—Somnolence—Doxorubicin—muscle cancer	0.000257	0.00199	CcSEcCtD
Lithium—GSK3A—Disease—KIT—muscle cancer	0.000255	0.000456	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF2—muscle cancer	0.000255	0.000455	CbGpPWpGaD
Lithium—Dyspepsia—Doxorubicin—muscle cancer	0.000254	0.00197	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—muscle cancer	0.000251	0.00194	CcSEcCtD
Lithium—Fatigue—Doxorubicin—muscle cancer	0.000249	0.00193	CcSEcCtD
Lithium—GSK3B—Disease—FOXO1—muscle cancer	0.000247	0.000442	CbGpPWpGaD
Lithium—Asthenia—Methotrexate—muscle cancer	0.00024	0.00185	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—muscle cancer	0.000238	0.00184	CcSEcCtD
Lithium—GSK3B—Developmental Biology—VEGFA—muscle cancer	0.000237	0.000424	CbGpPWpGaD
Lithium—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000236	0.00183	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—FOXO4—muscle cancer	0.000235	0.000419	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FOXO1—muscle cancer	0.000235	0.000419	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CNR1—muscle cancer	0.00023	0.000412	CbGpPWpGaD
Lithium—Body temperature increased—Doxorubicin—muscle cancer	0.000229	0.00177	CcSEcCtD
Lithium—Abdominal pain—Doxorubicin—muscle cancer	0.000229	0.00177	CcSEcCtD
Lithium—Diarrhoea—Methotrexate—muscle cancer	0.000228	0.00177	CcSEcCtD
Lithium—Dizziness—Methotrexate—muscle cancer	0.000221	0.00171	CcSEcCtD
Lithium—GSK3A—Immune System—MDM2—muscle cancer	0.000218	0.000389	CbGpPWpGaD
Lithium—Vomiting—Methotrexate—muscle cancer	0.000212	0.00164	CcSEcCtD
Lithium—Rash—Methotrexate—muscle cancer	0.00021	0.00163	CcSEcCtD
Lithium—Dermatitis—Methotrexate—muscle cancer	0.00021	0.00163	CcSEcCtD
Lithium—Headache—Methotrexate—muscle cancer	0.000209	0.00162	CcSEcCtD
Lithium—Asthenia—Doxorubicin—muscle cancer	0.000207	0.0016	CcSEcCtD
Lithium—GSK3B—Immune System—KIT—muscle cancer	0.000204	0.000365	CbGpPWpGaD
Lithium—GSK3A—Disease—MDM2—muscle cancer	0.000201	0.000359	CbGpPWpGaD
Lithium—Nausea—Methotrexate—muscle cancer	0.000198	0.00153	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—muscle cancer	0.000198	0.00153	CcSEcCtD
Lithium—GSK3A—Disease—PTGS2—muscle cancer	0.000194	0.000346	CbGpPWpGaD
Lithium—Dizziness—Doxorubicin—muscle cancer	0.000191	0.00148	CcSEcCtD
Lithium—GSK3B—Disease—KIT—muscle cancer	0.000189	0.000337	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF2—muscle cancer	0.000188	0.000336	CbGpPWpGaD
Lithium—Vomiting—Doxorubicin—muscle cancer	0.000184	0.00142	CcSEcCtD
Lithium—Rash—Doxorubicin—muscle cancer	0.000182	0.00141	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—muscle cancer	0.000182	0.00141	CcSEcCtD
Lithium—Headache—Doxorubicin—muscle cancer	0.000181	0.0014	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—KIT—muscle cancer	0.000179	0.000319	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FOXO1—muscle cancer	0.000173	0.00031	CbGpPWpGaD
Lithium—Nausea—Doxorubicin—muscle cancer	0.000172	0.00133	CcSEcCtD
Lithium—GSK3B—Immune System—MDM2—muscle cancer	0.000161	0.000287	CbGpPWpGaD
Lithium—GSK3B—Disease—MDM2—muscle cancer	0.000149	0.000265	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—muscle cancer	0.000143	0.000256	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MDM2—muscle cancer	0.000141	0.000251	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KIT—muscle cancer	0.000132	0.000236	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—muscle cancer	0.000107	0.000191	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MDM2—muscle cancer	0.000104	0.000186	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—muscle cancer	8.08e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—muscle cancer	7.9e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—muscle cancer	5.97e-05	0.000107	CbGpPWpGaD
